Abstract
The pharmacokinetics and psychomotor effects of medifoxamine, a 5 HT reuptake inhibitory antidepressant, were studied in healthy elderly volunteers after single and multiple dosing.
The elimination half life (t1/2z) after single doses of 300 mg was 2.8 h — almost identical to that found in young volunteers. After seven days of dosing at 100 mg three times daily the mean corrected AUC after 300 mg significantly increased from 1.04 to 1.34 mg.h.l−1 and t1/2z increased to 4.0 h (NS).
There were no significant changes in critical flicker fusion frequency, symbol digit substitution, continuous attention or choice reaction times.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Frewer LJ, Hindmarch I (1988) The effects of time of day, age and anxiety on choice reaction time. Hindmarch I, Aufdembrinke B, Ott H (eds) Psychopharmacology and reaction time Wiley, Chichester, pp 103–114
Hindmarch I (1975) A 1,4-benzodiazepine, temazepam (K3917), its effect on some psychological parameters of sleep and behaviour. Arzneimittelforschung (Drug Research) 25: 1836–1839
Kinirons MT, Jackson SHD, Kalra L, Trevit RT, Swift CG (1993) Computerised psychomotor performance testing: a comparative study of the single dose pharmacodynamics of minaprine and amitriptyline in young and elderly subjects. Br J Clin Pharmacol 36: 376–379
Poirier JL, Vieillefond H (1986) Effects of medifoxamine on psychomotor performance. Psychologie Medicale 18: 1925–1930
Randhawa MA, Hedges A, Johnston A, Turner P (1988) A psychopharmacological study to assess anti-muscarinic and central nervous effects of medifoxamine in normal volunteers. Human Psychopharmacology 3: 195–200
Saleh S, Johnston A, Turner P (1990a) Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans. Br J Clin Pharmacol 30: 621–624
Saleh S, Johnston A, Turner P (1990b) Medifoxamine: oral tolerance and pharmacokinetic study in healthy human volunteers. Eur J Clin Pharmacol 39: 169–171
Saleh S, Johnston A, Edeki T, Turner P (1990) Tolerability and kinetics of intravenous medifoxamine in healthy volunteers. Int Clin Psychopharmacol 5: 97–102
Scharbach H (1986) Comparative double-blind study of the activity and tolerance of medifoxamine and clomipramine in melancholic depression. Congres de Psychiatrie et de Neurologie de language Francaise. Masson, Paris, pp 763–765
Tignol J, Castaings G, Charrier PH, Chartres JP, Galidie JCI, Imbert D (1987) Results of a double-blind study of medifoxamine versus imipramine in major depressive disorders. Actualites Psychiatriques 7: 112–117
Tiplady B (1985) An automated test battery for the detection of changes in mental function and psychomotor performance. Br J Clin Pharmacol 20: 305P
Tiplady B (1988) A continuous attention test for the assessment of the acute behavioural effects of drugs. Psychopharmacology Bulletin 24: 213–216
Turner P (1968) Critical flicker frequency and centrally acting drugs. Br J Ophthalmol 52: 245–250
Wechsler D (1958) The measurement and appraisal of human intelligence, 4 th edn. Williams and Wilkins, Baltimore
Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6: 165–175
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gainsborough, N., Nelson, M.L., Maskrey, V. et al. The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers. Eur J Clin Pharmacol 46, 163–166 (1994). https://doi.org/10.1007/BF00199882
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199882